Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Global Tuberculosis Report 2020 - Reflections on the Global TB burden, treatment and prevention efforts.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2021
Same author

Evidences for lipid involvement in SARS-CoV-2 cytopathogenesis.

Cell death & disease·2021
Same author

Addressing challenges to rolling out COVID-19 vaccines in African countries.

The Lancet. Global health·2021
Same author

Zoonotic Tuberculosis - The Changing Landscape.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2021
Same author

Accelerating development of new shorter TB treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19 pandemic.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2021
Same author

Lethal zoonotic coronavirus infections of humans - comparative phylogenetics, epidemiology, transmission, and clinical features of coronavirus disease 2019, The Middle East respiratory syndrome and severe acute respiratory syndrome.

Current opinion in pulmonary medicine·2021

Video Experimental Relacionado

Updated: May 22, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

Ampliar las intervenciones para lograr el control mundial de la tuberculosis: progreso y nuevos desarrollos.

Mario Raviglione1, Ben Marais, Katherine Floyd

  • 1STOP TB Department, WHO, Geneva, Switzerland.

Lancet (London, England)
|May 22, 2012
PubMed
Resumen

Los esfuerzos mundiales de control de la tuberculosis están progresando, acercándose a los Objetivos de Desarrollo del Milenio, pero persisten desafíos como la colaboración entre el VIH / tuberculosis y la resistencia a los medicamentos. La inversión continua y los enfoques multidisciplinarios son vitales para la eliminación de la tuberculosis.

Más Videos Relacionados

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

Videos de Experimentos Relacionados

Last Updated: May 22, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

Área de la Ciencia:

  • Salud Global La salud global.
  • Enfermedades infecciosas Enfermedades infecciosas.
  • Política de salud pública Política de salud pública.

Sus antecedentes:

  • La tuberculosis (TB) sigue siendo una causa significativa de mortalidad en todo el mundo.
  • Las revisiones anteriores destacaron los esfuerzos y desafíos de control.
  • Se ha avanzado hacia los objetivos de 2015, con África como excepción.

Objetivo del estudio:

  • Revisar los avances recientes en los esfuerzos mundiales de control de la tuberculosis.
  • Identificar los desafíos actuales y las amenazas emergentes en el control de la TB.
  • Hacer hincapié en la necesidad de estrategias actualizadas y compromiso sostenido.

Principales métodos:

  • Revisión de los recientes datos e iniciativas mundiales de control de la tuberculosis.
  • Análisis del progreso hacia los Objetivos de Desarrollo del Milenio y los objetivos de Stop TB Partnership.
  • Evaluación de los desafíos, incluida la colaboración TB / VIH, la resistencia a los medicamentos y los impactos de las enfermedades no transmisibles.

Principales resultados:

  • La mayoría de las regiones están en camino de cumplir con los objetivos de reducción de la incidencia y la mortalidad por tuberculosis para 2015, excepto África.
  • Los desafíos persisten en la ampliación de las actividades de colaboración entre la TB y el VIH.
  • La tuberculosis emergente resistente a los medicamentos plantea una amenaza significativa.
  • Nuevas pruebas de diagnóstico y medicamentos prometedores están llegando a estar disponibles.
  • Las enfermedades no transmisibles y las malas condiciones de vida aumentan la vulnerabilidad.

Conclusiones:

  • El logro de los objetivos internacionales de control de la TB requiere políticas y servicios de salud nacionales óptimos.
  • La inversión continua en nuevos enfoques y estrategias es crucial.
  • La incertidumbre financiera y los déficits ponen en riesgo las ganancias recientes.
  • La perseverancia y el compromiso renovado son esenciales para el control y la eliminación de la TB.